Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by Van ECK Associates Corp

Van ECK Associates Corp lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 490.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 111,500 shares of the biotechnology company’s stock after purchasing an additional 92,610 shares during the period. Van ECK Associates Corp owned approximately 0.08% of Arrowhead Pharmaceuticals worth $9,088,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. BlackRock Inc. purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter worth about $1,208,838,000. Geode Capital Management LLC lifted its stake in Arrowhead Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock valued at $216,799,000 after buying an additional 133,921 shares in the last quarter. Baker BROS. Advisors LP lifted its stake in Arrowhead Pharmaceuticals by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company’s stock valued at $144,441,000 after buying an additional 504,883 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Arrowhead Pharmaceuticals by 0.3% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company’s stock worth $138,619,000 after buying an additional 6,264 shares during the period. Finally, Fred Alger Management LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 497.4% in the fourth quarter. Fred Alger Management LLC now owns 1,832,997 shares of the biotechnology company’s stock worth $121,693,000 after buying an additional 1,526,164 shares during the period. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR opened at $82.74 on Wednesday. The firm has a market capitalization of $11.65 billion, a PE ratio of -36.77 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $22.73 and a 1 year high of $95.49. The company has a current ratio of 5.90, a quick ratio of 5.90 and a debt-to-equity ratio of 1.77. The firm’s fifty day simple moving average is $83.71 and its 200 day simple moving average is $73.91.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The firm had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The firm’s revenue was up 171.0% on a year-over-year basis. During the same quarter last year, the company earned ($1.26) earnings per share. On average, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.51 EPS for the current year.

Insider Activity

In related news, Director Michael S. Perry sold 11,600 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares in the company, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director directly owned 31,600 shares in the company, valued at $2,747,936. This trade represents a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is currently owned by insiders.

Arrowhead Pharmaceuticals News Roundup

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Phase 3 SHASTA-3 and SHASTA-4 results indicated that plozasiran reduced acute pancreatitis episodes in patients with severe hypertriglyceridemia. The 12-month data strengthen the investment case for the program and could improve confidence in its commercial potential. Arrowhead Pharmaceuticals presents Phase 3 SHASTA-3 and SHASTA-4 data
• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and set a $120 price target, implying roughly 45% potential upside from the referenced share price.
• Positive Sentiment: Chardan Capital also reaffirmed its “buy” rating, with a $115 target representing approximately 39% upside, while RBC maintained an “outperform” rating and a $100 target, or about 21% upside. The cluster of bullish targets signals continued Wall Street confidence in ARWR’s pipeline. Analysts are bullish on Arrowhead Pharmaceuticals and BioNTech
• Neutral Sentiment: The company’s discussion of 12-month SHASTA-3 and SHASTA-4 results provides additional clinical detail, but the transcript itself does not represent a new regulatory approval or commercial launch. Arrowhead discusses SHASTA-3 and SHASTA-4 12-month results

Analyst Ratings Changes

ARWR has been the topic of several research analyst reports. B. Riley Financial lifted their price objective on shares of Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Piper Sandler restated an “overweight” rating and issued a $126.00 target price (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Chardan Capital reaffirmed a “buy” rating and issued a $115.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday. JPMorgan Chase & Co. lifted their price target on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, Sanford C. Bernstein upped their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $98.42.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.